How 3 Top Chefs Are Addressing Factory Farming
Chefs have a unique responsibility—and opportunity—to cook according to their values. We turned to three of our favorite food industry […]
Listen, panettone can get a bad rap. One look at the traditional, Italian sweet bread loaf speckled with candied fruits […] Fox News Flash top headlines for Nov. 4 Fox News Flash top headlines for Nov. 4 are here. Check out […] Tomato-peach tarte tatin Serve this showstopper as a vegetarian entrée, or slice it smaller for a predinner nibble. Active time: 20 minutes; […] Fox News Flash top headlines for June 29 Fox News Flash top headlines for June 29 are here. Check out […] CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the […] Breakthrough in the fight to end maternal mortality: Rapid urine test could detect dangerous pregnancy-related stroke risk in 3 minutes […] MONDAY, March 11, 2019 — For young adults, drugs and distracted driving are well-recognized health threats. Far less attention is […] Newly engaged woman is given a 3 percent chance of survival after contracting double pneumonia and sepsis A 28-year-old bride-to-be […] BOSTON, Dec. 13, 2018 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization […]3
Got Leftover Panettone? Bobby Flay Has 3 Genius Ways to Use It
Eyeball tattoos allegedly left 'Blue Eyes White Dragon' woman blind for 3 weeks: 'That was pretty brutal'
3 Healthy Recipes for Your Summer Tomatoes
Child exposed to E. coli at San Diego County Fair dies, 3 others sickened: officials
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Rapid urine test could detect pregnancy-related stroke risk in minutes
1 in 3 Young Adults Suffers From Loneliness in U.S.
Bride-to-be reportedly given 3 percent chance of survival after contracting deadly infection
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes